Trial Profile

An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; JNJ 64264681 (Primary) ; JNJ 70218902 (Primary) ; JNJ-74856665 (Primary) ; JNJ-75348780 (Primary) ; Onametostat (Primary) ; Safimaltib (Primary)
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

13 Apr 2026 Planned number of patients changed from 80 to 120.
07 Apr 2026 Planned End Date changed from 21 Jan 2028 to 30 Oct 2028.
03 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com